Start Phase 2b/3 study of dipraglurant for Parkinson's disease LID
Delivered by the deadline
AI-assessed · human review in progress Found and assessed by AI from the cited sources. Shown with its evidence; it is not counted in any Kept Score until confirmed.
- Announced
- 11 Mar 2021
- Due
- 30 Jun 2021
- Delivered
- June 2021
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“H1 21 - Phase 2b/3 study starting: dipraglurant for Parkinson's disease LID”
What we found
Evidence strength A What the grades mean
The 2022 20-F says the Phase 2b/3 pivotal trial of dipraglurant in PD-LID has been conducted since June 2021, within the H1 2021 deadline. Filings from July 2021 describe the trial as underway.
-
A Addex Therapeutics Ltd. 20-F filed 2022-03-10
“We are currently conducting a placebo-controlled Phase 2b/3 pivotal clinical trial of dipraglurant in PD-LID patients since June 2021.” ✓ confirmed on the page
-
A Addex Therapeutics Ltd. 6-K filed 2021-07-01
“Addex’s lead product candidate, dipraglurant (mGlu5 negative allosteric modulator or NAM) is in a pivotal registration clinical trial for Parkinson’s disease levodopa induced dyskinesia (PD-LID).” ✓ confirmed on the page
Checked 27 Oct 2026.
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Clinical milestone
- Indicative materiality
- Medium rules
- Action
- Start
- Deliverable
- Phase 2b/3 study of dipraglurant for Parkinson's disease LID
- In the company’s control
- High
- Specificity
- High
How this entry was checked
- Commitment recordedThe company's words were matched word for word against the filing.
- First checkAn AI model, Claude (Anthropic), read the company's later filings and recorded the outcome with a quoted passage.
Not yet confirmed. Shown on the record, but it will not count in any score until it is confirmed. How verification works
Are you Addex Therapeutics Ltd.? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2021-ADXN-025621 · Corrections policy